Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Strongbridge Biopharma Plc (NASDAQ: SBBP) today and set a price target of $17. The company’s shares opened today at $4.82.
Piros wrote:
“We believe Strongbridge has reached an inflection point, where the company is poised to deliver value from clinical development of Recorlev and commercial deployment of KEVEYIS. Valuation Summary We arrive at our 12-month price target of $17/share by assessing the after-tax, risk- adjusted NPV of potential future cash flows from KEVEYIS and Recorlev for the treatment of primary periodic paralysis and Cushing’s syndrome, respectively.”
According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.5% and a 46.4% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Global Blood Therapeutics, and Bellicum Pharmaceuticals.
Strongbridge Biopharma Plc has an analyst consensus of Strong Buy, with a price target consensus of $16.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.25 and a one-year low of $3.85. Currently, Strongbridge Biopharma Plc has an average volume of 580.4K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SBBP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.
